Breakthrough Precision Treatment Tools
and Next-Generation Drug Development
Cardiovascular disease (CVD) is a pandemic --- causes one in every four deaths in the U.S., one in three worldwide.
Now there is a new weapon against this pandemic --- a non-invasive imaging diagnostic that can diagnose cardiovascular disease early before it's too late, enabling precision treatment and the development of next generation drugs for early treatment.
In this video you will learn about:
- Reducing clinical trial costs and duration by 50% through highly specific non-invasive cardiovascular disease assessment
- Ushering in the new era of true CVD precision medicine treatment made possible by applying AI to CVD plaque morphology analytics
- Optimizing patient treatments and outcomes using predictive non-invasive CVD biomarker measurements
- Slowing and preventing CVD progression towards interventional care with earlier diagnosis and treatment
- Improving clinical trial patient selection with stroke/MACE prediction that is 35%+ more accurate vs. current standard of care
- Eliminating unnecessary cath lab procedures by overcoming inaccuracies in today's CVD first-line diagnostics
- Never-before-possible plaque morphology measurements reveal treatment effectiveness of new CVD drug in ongoing clinical trial
Presenters:
Matthew Budoff, MD - Investigator, The Lundquist Institute; Professor of Medicine, David Geffen School of Medicine at UCLA; Program Director and Director of Cardiac CT, Division of Cardiology, Harbor-UCLA Medical Center
Dr. Budoff has author or coauthored more than 50 books and book chapters and more than 2000 articles and abstracts. He has received numerous research grants from the National Institutes of Health and has been invited to lecture at cardiology conferences around the world. In addition to his 2015 appointment as the Endowed Chair of Preventive Cardiology at Harbor-UCLA Medical Center, he has been recognized for his work by the Society of Cardiovascular Computed Tomography, from which he received the Gold Medal Award and recently designated as Master of the Society of Cardiovascular Computed Tomography (MSCCT), and has been inducted into the European Academy of Sciences. Dr. Budoff has been named to “America’s Top Doctors” for each of the past 9 years. In 2011, he was named a US News Top Doctor for cardiology, was awarded the Albert Nelson Marquis Lifetime Achievement Award in 2018 and named to “The world’s most influential scientific researchers” in 2018 and 2019. lundquist.org/matthew-budoff-md
Andrew J. Buckler - Founder, President, CTO of Elucid
A true pioneer in molecular and quantitative imaging, Buckler has been researching, studying, and publishing in the field of non-invasive imaging modalities for more than 30 years. He has collaborated with researchers around the world to publish more than 70 peer-reviewed journal articles on biomedical and molecular imaging. Additionally, he has led large engineering teams at Eastman Kodak, Hewlett Packard, Siemens, and Philips. He and his teams have invented, developed, and launched dozens of products, generating well over a billion dollars in revenue. Buckler is also the program director and co-chair of the Quantitative Imaging Biomarkers Alliance. QIBA was formed to unite researchers, healthcare professionals, and the industry to advance quantitative imaging and the use of imaging biomarkers in clinical trials and clinical practice. The scope including both definition of methodology as well as the application of that methodology to selected biomarkers.
ElucidVivo clinical solutions provide comprehensive and accurate clinical insights, based on ground-truth histology and machine learning, enabling unprecedented precision healthcare for vascular disease.
elucidvivo.com
Host:
William Kazman - Founding Partner of GeneWorx Capital
MIT-trained engineer/entrepreneur and enthusiast of the biological revolution and its accelerating global impact. Applying 30+ years of engineering and company-building skills to identify early stage biological innovations with disruptive potential, and help their inventors / scientists / entrepreneurs transform them into high value enterprises.
GeneWorx Capital is a venture development firm in Cambridge, MA comprised of MIT technologists, former Wall Street VC investors and Silicon Valley entrepreneurs on a mission to accelerate the growth of emerging life science companies.
GeneWorxCapital.com